

# Chapter 7

## Bacterial Signal Peptidases



Mark Paetzel

**Abstract** Signal peptidases are the membrane bound enzymes that cleave off the amino-terminal signal peptide from secretory preproteins. There are two types of bacterial signal peptidases. Type I signal peptidase utilizes a serine/lysine catalytic dyad mechanism and is the major signal peptidase in most bacteria. Type II signal peptidase is an aspartic protease specific for prolipoproteins. This chapter will review what is known about the structure, function and mechanism of these unique enzymes.

**Keywords** Protein secretion · Signal peptide · Signal peptidase · Bacterial lipoprotein · Periplasmic protease

### Introduction

The basic elements of the general protein secretion system are conserved in all cells; archaeal (Pohlschroder et al. 2018), bacterial (Chatzi et al. 2013; Driessen and Nouwen 2008; Tsirigotaki et al. 2017) and eukaryotic (Nyathi et al. 2013; Voorhees and Hegde 2016). A key feature of this system is the signal peptide. The signal peptide or signal sequence is approximately 20–30 residues in length and located at the amino-terminus of secretory proteins (preproteins). The signal peptide is essential for targeting to the cytoplasmic membrane or endoplasmic reticulum membrane and also translocation across the membrane. Upon translocation of secretory proteins, the signal peptide is cleaved off.

The protein machinery of the general secretion system helps catalyze the targeting and translocation events. Bacterial protein secretion occurs predominantly as a post-translational translocation event. In other words, preproteins are fully synthesized and released from the ribosome within the cytoplasm, and then targeted to and translocated across the cytoplasmic membrane. Typically, the preprotein first encounters the protein SecB that functions as a holdase, keeping the preprotein sol-

---

M. Paetzel (✉)


Department of Molecular Biology and Biochemistry, Simon Fraser University, South Science Building 8888 University Drive, Burnaby, BC V5A 1S6, Canada  
e-mail: [mpaetzel@sfu.ca](mailto:mpaetzel@sfu.ca)

uble and in a translocationally competent form that can fit through the translocation channel SecYEG. The ATPase SecA feeds the preprotein through SecYEG step-wise. The energy for translocation across the membrane comes from ATP hydrolysis and the proton motive force. Once the carboxy-terminal region of the preprotein has been pushed through the translocase, the signal peptide is thought to partition into the lipid bilayer via a lateral gate in the SecYEG channel. The preprotein is then tethered to the membrane via the signal peptide. This membrane-tethered preprotein is the natural substrate of signal peptidase (SPase). It has been shown that removal of the signal peptide is essential in order for secretory proteins to be released from the cytoplasmic membrane (Dalbey and Wickner 1985). Limited proteolysis (Randall 1983) and deletion studies (Kaderbhai et al. 2008) are consistent with the carboxy-terminal region of preproteins being nearly or completely translocated across the cytoplasmic membrane before the signal peptide is cleaved off.

There are two types of bacterial SPase referred to as type I and type II. SPase I cleaves off the signal peptide from the majority of secreted proteins. It is an endopeptidase that utilizes a serine nucleophile and has the enzyme commission number EC 3.4.21.89. In the MEROPS protease database it is in clan SF and the family S26. Archaea also have an SPase I, but their sequences reveal that they maybe more related to a component of the eukaryotic signal peptidase complex. SPase II cleaves off the signal peptide from bacterial lipoproteins, proteins that associate with the membrane via an amino-terminal lipid modification. SPase II is an endopeptidase that utilizes aspartate catalytic residues and has the enzyme commission number EC 3.4.23.36. In the MEROPS protease database, it is in clan AC and the family A8. No homolog of SPase II has been found in an archaeal genome. Before discussing the research related to the structure, function and mechanism of the bacterial and archaeal SPase, the preprotein signal peptide will be briefly described.

The signal hypothesis states that secretory proteins contain an amino-terminal sequence (signal sequence) which helps the target secretory protein to the membrane and that after translocation across the membrane, the signal sequence is cleaved off by a specific peptidase (signal peptidase, SPase) (Blobel and Dobberstein 1975a, b; Milstein et al. 1972; Sabatini et al. 1971). Since this groundbreaking discovery, a great deal has been learned about the structure and function of signal peptides.

The general features of signal peptides are conserved across evolution. They have an amino-terminal region of sequence (1–5 residues in length) called the n-region that has a net-positive charge. The n-region is followed by a stretch of 7–15 hydrophobic residues (often leucines) labeled the h-region. Just beyond the h-region are 3–7 residues termed the c-region. This c-region contains the specificity residues for SPase recognition and cleavage. The consensus sequence for the cleavage site consists of small aliphatic residues at the –3 and –1 positions relative to the cleavage site (or P1 and P3 positions in Schechter and Berger nomenclature (Berger and Schechter 1970). This is often called the Ala-X-Ala rule because of the preference for alanine at the –3 and –1 position (Perlman and Halvorson 1983; von Heijne 1983, 1985), while there is a lack of preference for specific residues at the –2 position, thus the X designation (Fig. 7.1a). Signal peptide length is conserved as well. The average eukaryotic signal peptide is approximately 23 residues in length, while the average



◀Fig. 7.1 Bacterial secretory preproteins. **a** Secretory proteins have three regions within their signal peptide: the n-region has a net-positive charge, the h-region contains predominantly aliphatic residues such as leucine, and the c-region contains the specificity cleavage site for signal peptidase. Small aliphatic residues such as alanine are preferred at the P1 and P3 positions (also referred to as the  $-1$  and  $-3$  positions). The molecular structure of the last three residues of the c-region are drawn in an extended conformation in order to show the alternating up and down topology that leads to the “Ala-X-Ala” SPase preference. The h-region is shown as a rectangle to symbolize an  $\alpha$ -helical conformation. **b** Bacterial prolipoproteins are synthesized with a signal peptide that has similarities to secretory proteins sequences with the exception that the c-region contains the so-called “lipobox” with the consensus sequence leucine(P3)-alanine(P2)-glycine(P1)-cysteine(P1'). The P1' cysteine is covalently modified by diacylglycerol. This is the substrate of SPase II

Gram-negative bacterial signal peptide is approximately 25 residues in length and the average Gram-positive bacterial signal peptide is approximately 32 residues in length (Nielsen et al. 1997a, b). It has been hypothesized that the differences observed in signal peptide length may reflect the differences in the thickness of the lipid bilayer in the different membranes.

Researchers continue to develop increasingly more accurate signal peptide prediction servers (Choo et al. 2009; Leversen et al. 2009; Petersen et al. 2011; Savojardo et al. 2018; Wang et al. 2018). The availability of genome sequences (UniProt 2013) and improved proteomic methods have vastly increased the number of predicted and experimentally verified signal peptide sequences. Biophysical and modeling studies are consistent with the h-region of the signal peptide being helical within the hydrophobic environments of detergent micelles or membrane (Bechinger et al. 1996; McKnight et al. 1991a, b; Rizo et al. 1993; Sankaram et al. 1994; Wang et al. 1993). Modeling and structural analysis is consistent with the c-region of the signal peptide being in the extended  $\beta$ -strand conformation (Paetzel et al. 1998, 2002; Ting et al. 2016). The substrate cleavage-site being in a  $\beta$ -conformation is the classical conformation within protease binding sites (Tyndall et al. 2005). The structural and biophysical information now available regarding the conformation of signal peptides is in agreement with the prediction that was made in 1983 (von Heijne 1983).

Occasionally, unusual signal peptide variants are recognized. For example, it has been observed that in *Porphyromonas gingivalis* and other *Bacteroidetes* species  $>50\%$  of the preproteins have a glutamine at the P1' position (Bochtler et al. 2018). This generates an amino-terminal glutamine after SPase I processing. The newly formed amino-terminal glutamines are cyclized to pyroglutamate by glutaminyl cyclase. These pyroglutamate containing proteins do not appear to be specific to inner membrane proteins, periplasmic proteins, outer membrane proteins or extracellular proteins. It is not yet clear what role the amino-terminal pyroglutamate plays in the *Bacteroidetes* physiology but it has been shown that glutaminyl cyclase is essential in these species.

There has been significant effort put into the optimization of signal peptides for the secretion of industrially important recombinant proteins (Freudl 2018; Ghahremanifard et al. 2018; Low et al. 2013; Molino et al. 2018; Selas Castineiras et al.

2018; Ujiie et al. 2016; Zhang et al. 2018). A recent comprehensive review on signal peptides has been published (Owji et al. 2018).

Bacterial secretory proteins that utilize bound cofactors often need to fold within the cytoplasm in order to assemble properly and bind their cofactor. These folded proteins use the twin arginine translocation (Tat) secretion system rather than the general secretion system. The name comes from the sequence within the signal peptide. These signal peptides have a so-called twin-arginine motif (SRRxFLK) located between the n- and h-regions. There are 27 known Tat substrates in *E. coli* (Tullman-Ercek et al. 2007) and it has been shown that SPase I cleaves off Tat signal peptides (Luke et al. 2009).

Archaea have an evolutionarily similar general secretion system to that seen in bacteria and eukaryotes which includes similar signal peptide characteristics (Bardy et al. 2003). The similarity allows for bacterial SPase I to recognize and cleave archaeal preproteins. *E. coli* SPase I is capable of cleaving pre- $\alpha$ -amylase from *Thermococcus kodakarensis* (Muhammad et al. 2017). Genomic analysis suggests that protein secretion in archaea may be more similar to that of eukaryotes than to prokaryotes. For example, archaea lack a SecA (ATPase) homolog, therefore archaeal translocation maybe more energetically similar to the eukaryotic system where co-translational translocation is the main mechanism of transport across the membrane. Consistent with this idea, archaea also appear to lack a post-translational holdase type of targeting chaperone like SecB (Pohlschroder et al. 2018). Subtle differences in archaeal signal peptides have led researchers to develop a signal peptide prediction server trained on a set of characterized archaeal signal peptides (Bagos et al. 2009).

Bacterial lipoproteins are soluble hydrophilic proteins located in the bacterial cell wall. These proteins are tethered or anchored to the inner or outer membrane by permanent covalent lipid modifications. They have a diacylglycerol linked to an amino-terminal cysteine via a thioether linkage. Many of the bacterial lipoproteins perform functions that are essential to cellular viability. They have roles in: membrane and cell shape maintenance, outer membrane protein assembly, outer membrane stabilization, transport of molecules, energy production, signal transduction, virulence mechanisms, adhesion, digestion, sensing, growth, cell motility and many more cellular functions.

Bacterial lipoproteins are initially synthesized as preprolipoproteins that have a signal sequence for targeting and translocation via the general secretion system pathway (Driessens and Nouwen 2008) (Fig. 7.1b). The signal peptides of lipoproteins are very similar to those for secretory proteins in that they are approximately 20 residues in length and have a net positively charged region (n-region) followed by a stretch of hydrophobic residues (h-region) and then a recognition sequence region (c-region). Within the c-region is the SPase II recognition sequence called the “lipobox”. The consensus sequence for the lipobox is leucine most often at the  $-3$  (P3) position relative to the cleavage site, alanine most often at the  $-2$  (P2) position, glycine most often at the  $-1$  (P1) position and cysteine always at the  $+1$  (P1') position. The sequence variations that are observed in the lipobox are [LVI] [ASTVI][GAS]C (Chimalapati et al. 2013; Kovacs-Simon et al. 2011; LoVullo et al. 2015; Nakayama et al. 2012; Narita and Tokuda 2017; Zuckert 2014). The  $+1$  (P1') cysteine is modified

with diacylglycerol (DAG) via a thioether linkage. This reaction is catalyzed by lipoprotein diacylglyceryl transferase (Lgt) and occurs in the inner membrane using the phospholipid within the inner membrane as substrate (Mao et al. 2016; Sankaran et al. 1997). The DAG-modified protein is then referred to as a prolipoprotein and is the substrate for type II signal peptide (SPase II) which cleaves off the signal peptide (Chimalapati et al. 2013). The scissile bond is the peptide bond preceding the invariant cysteine within the lipobox. Most SPase II will not cleave preprolipoproteins (protein without DAG-modification) (Inouye et al. 1983). For many Gram-positive bacterial species this is the end of lipoprotein synthesis; these mature lipoproteins are tethered to the outer leaflet of the cytoplasmic membrane, preventing them from diffusing away from the surface of the bacteria (Nguyen and Gotz 2016). For Gram-negative species another modification can occur. A fatty acid is attached, via an amide linkage, to the  $\alpha$ -amino group of amino-terminal cysteine. This reaction is catalyzed by the enzyme lipoprotein N-acyl transferase (Lnt) (Buddelmeijer and Young 2010; Hillmann et al. 2011; Noland et al. 2017). The mature lipoprotein with three acyl-chains can then be shuttled to the outer membrane via the lipoprotein outer membrane localization (LOL) machinery (Konovalova and Silhavy 2015; Tokuda and Matsuyama 2004), or stay within the inner membrane if there is a retention signal which often consists of an aspartic acid at the +2 (P2') position (Seydel et al. 1999; Terada et al. 2001).

The database DOLOP lists and categorizes both predicted and experimentally verified bacterial lipoproteins (Babu et al. 2006; Madan Babu and Sankaran 2002), but this database has not been updated since 2005. A video procedure for the purification of lipoproteins via Triton X-114 detergent extraction and electrophoresis, followed by chemical characterization by proteolysis, solvent extraction and mass-spectrometry is available (Armbruster and Meredith 2018). There are many recent reviews on bacterial lipoproteins (Hutchings et al. 2009; Konovalova and Silhavy 2015; Kovacs-Simon et al. 2011; LoVullo et al. 2015; Narita and Tokuda 2017; Zuckert 2014). For a review on the chemical characterization of both Gram-negative and Gram-positive bacterial lipoproteins by mass-spectrometry see the review by Nakayama et al. (2012). A lipoprotein signal peptide prediction server called LipoP is available (Juncker et al. 2003; Rahman et al. 2008). Great progress has been made in understanding the enzymes in the bacterial lipoprotein synthetic pathway and crystal structures have been solved for each of the enzymes involved: Lgt (Mao et al. 2016), Lnt (Noland et al. 2017) and SPase II (Vogeley et al. 2016). Only SPase II will be discussed in this chapter.


## Gram-Negative Type 1 Signal Peptidase

*Escherichia coli* SPase I was the first bacterial SPase I to be studied and is the most thoroughly characterized SPase to date. The first observation of bacteria SPase I activity was in *E. coli* membranes using a nascent bacteriophage f1 pre-coat protein as the substrate (Chang et al. 1978). *E. coli* SPase I was also the first bacterial SPase I

to be purified. Bacteriophage M13 procoat protein was used as the substrate to assess the 6,000 fold purification (Zwizinski and Wickner 1980). A proteoliposome assay showed that only purified *E. coli* SPase I and phospholipid were needed for preprotein processing (Watts et al. 1981). The pH optimum of *E. coli* SPase I is 8.5–9.0 and it is inhibited by NaCl concentrations above 160 mM and MgCl<sub>2</sub> concentrations above 1 mM. The enzyme has been shown to be essential for cell growth (Date 1983). *E. coli* SPase I is the product of the *lepB* gene, is 324 residues in length, and has a calculated molecular mass of 35,960 Da and a theoretical isoelectric point of 6.9. Quantitative western blot analysis is consistent with approximately 1000 SPase I molecules per cell (van Klompenburg et al. 1995). The current residue numbering system for *E. coli* SPase I is different by one residue from the numbering system used in earlier work. This is due to an error in the originally reported sequence of the *E. coli* enzyme (Wolfe et al. 1983); Arg42 in the originally reported sequence is actually Ala42. In addition there is glycine residue (Gly43) just after the Ala42 that was not in the originally reported sequence. The insertion moves the sequence up one number after that point. Therefore, in the current system, residues 1–41 are consistent with the old numbering and residues 44–324 are correct in sequence but the numbering is one residue different from the old numbering. The sequencing error corresponds to residues within the cytoplasmic region, between the two transmembrane segments. The numbering system used in this chapter matches that in the UniProt sequence database (accession number: P00803).

Protease accessibility assays show that *E. coli* SPase I is an integral membrane protein and the majority of the protein chain is on the outside of the cytoplasmic membrane (Moore and Miura 1987; Wolfe et al. 1983). Enzyme-fusion assays are consistent with both the amino- and carboxy-termini facing the periplasm (San Millan et al. 1989). The interface between the two transmembrane segments in *E. coli* SPase I has been modeled based on disulfide mapping (Whitley et al. 1993). It was found that residue pairs 3–76, 4–76, 4–77, –4–80, and 7–76 are likely in close proximity. Modeling is consistent with the two transmembrane helices packing against each other in a left-handed supercoil with an i, i + 3/i, i + 4 grooves-into-ridges arrangement. Site-directed mutagenesis and deletion studies show that the first transmembrane segment (residues 4–28) and cytoplasmic region (residues 29–57) are not essential for catalytic activity. The second transmembrane segment (residues 58–76) is essential for activity and for initiating the translocation of the periplasmic region (residues 77–324) where the protease active site resides (Bilgin et al. 1990) (Fig. 7.2). It has been shown that highly purified and concentrated *E. coli* SPase I will cleave itself in a intermolecular fashion within its cytoplasmic region (Talarico et al. 1991). Since this cleavage site region is on the opposite side of the cytoplasmic membrane from the SPase I active site, it is not likely this is a common occurrence in vivo, although disruption of the membrane or mistakes in SPase I assembly could allow for this type of cleavage.

Early studies tried to classify the mechanism of *E. coli* SPase I based on sensitivity to standard protease inhibitors (Zwizinski et al. 1981). These experiments were inconclusive and suggested that this enzyme may utilize a unique mechanism. Site-directed mutagenesis of conserved ionizable residues was consistent with Ser91



**Fig. 7.2** The membrane topology and protein fold of *E. coli* SPase I. The transmembrane segments, not part of the crystal structure, are represented by rectangles. The nucleophilic Ser91 and general base Lys146 are labeled. The  $\beta$ -ribbon and domain 2 region not normally observed in the Gram-positive SPase I enzymes are labeled (PDB: 1B12)

and Lys146 being essential for catalytic activity (Black 1993; Black et al. 1992; Paetzel et al. 1997; Sung and Dalbey 1992; Tschantz et al. 1993). Therefore, a Ser/Lys catalytic dyad mechanism was proposed.

The first three-dimensional structure of a SPase I was that of *E. coli* SPase I (Paetzel et al. 1998). A soluble catalytically active enzyme was produced, lacking the two amino-terminal transmembrane segments ( $\Delta 2-76$ ) (Tschantz et al. 1995). This active periplasmic region of *E. coli* SPase I produced ordered diffraction quality crystals (Paetzel et al. 1995). Crystal structures of this enzyme are available in complex with a  $\beta$ -lactam type of inhibitor (Paetzel et al. 1998), in complex with a lipopeptide base inhibitor called arylomycin (Paetzel et al. 2004), in complex with arylomycin and  $\beta$ -sultam inhibitor (Luo et al. 2009), and in complex with a lipoglycopeptide version

of arylomycin (Liu et al. 2011a). In addition, a structure of *E. coli* SPase I with a free active site is available (Paetzel et al. 2002).


The crystal structures reveal that SPase I is primarily constructed of  $\beta$ -sheets. There are two antiparallel  $\beta$ -sheet domains (domain I and domain II) and an extended  $\beta$ -hairpin that extends from domain I (Fig. 7.2). Domain I contains the catalytic residues and has a similar protein fold to that of the proteinase domain in the UmuD protein of the SOS mutagenesis system (Paetzel and Strynadka 1999). Sequence alignments reveal that domain II is much smaller or missing in Gram-positive SPase I. A disulfide bond (Cys171–Cys177) resides within domain II of *E. coli* SPase I but mutagenesis has shown it to be nonessential (Sung and Dalbey 1992). Almost all of the conserved SPase I residues are located near the active site in domain I.

The catalytic center of SPase I resides at the end of a substrate binding groove that is provided by a missing  $\beta$ -strand of a would-be  $\beta$ -barrel within domain I. The strand and the loop region that makes up the edges of the binding groove run parallel to one another. Modeling studies based on the inhibitor complexes and the constraints related to the lipid bilayer of the inner membrane suggest that the c-region of the signal peptide within the preprotein substrate binds in a parallel  $\beta$ -strand conformation (Paetzel et al. 1998, 2002). This binding mode is in agreement with previous predictions (von Heijne 1983). The nucleophile Ser91 resides on a loop following the first  $\beta$ -strand. The general-base Lys146 resides on a  $\beta$ -strand with its N $\gamma$  atom within hydrogen bonding distance to the Ser91O $\gamma$  (Fig. 7.3). Lys146 N $\gamma$  is also within hydrogen bonding distance to Ser279O $\gamma$ . This is a conserved residue and site-directed mutagenesis experiments show that it is important for optimal activity (Klenotic et al. 2000). The oxyanion hole is constructed from the mainchain NH group of Ser91 and the side chain hydroxyl group of the Ser89. In vivo and in vitro analysis of site-directed mutants at this position are consistent with Ser89 playing a role in transition state stabilization (Carlos et al. 2000).

The substrate specificity binding pockets that lead to the active site explain the preference for alanine at the  $-1$  (P1) and  $-3$  (P3) position in preproteins (Fig. 7.3). The shallow and hydrophobic S1 substrate specificity binding pocket is made of atoms from the residues: Met92, Ile145, Leu96 and Ile87. The shallow and hydrophobic S3 substrate specificity binding pocket is constructed with atoms from residues: Phe85, Ile87, Ile102, Val133, Ile145 and Asp143. Site-directed mutagenesis, mass-spectrometry and molecular modeling were used to probe the importance of residues in the SPase I binding pockets. It was observed that Ile87 and Ile145, residues that divide the S1 and S3 binding pockets (Fig. 7.3), are important for specificity as well as cleavage site fidelity (Ekici et al. 2007; Karla et al. 2005). NMR analysis has recently been employed to look at the details of the interactions between SPase I and the signal peptide (De Bona et al. 2012; Musial-Siwek et al. 2008a, b).

*E. coli* SPase I has an extensive hydrophobic surface that runs along domain I and leads to the active site. This hydrophobic surface and the orientation of active site residues provide clues as to how the catalytic domain lays on the membrane surface. Chemical modification and site-directed mutagenesis experiments are consistent with Trp301 and Trp311 being important for activity and these residues reside along the hydrophobic surface (Kim et al. 1995a, b). Biophysical analysis has shown

**Fig. 7.3** The active site region of *E. coli* SPase I. The regions corresponding to the S1 and S3 substrate specificity pockets are labeled. Dashed lines correspond to important hydrogen bonds within the active site. The coordinates used are from a structure with a free active site. An ordered, and potentially catalytic, water at the correct distance and angle to the general base and modeled scissile carbonyl is labeled (PDB: 1KN9)




that the catalytic domain of *E. coli* SPase I penetrates into the membrane and that phosphatidylethanolamine, the most abundant phospholipid in the *E. coli* inner membrane, mediates the association (van Klompenburg et al. 1997, 1998). Kinetic analysis shows that detergent or lipid is required for optimal activity of the soluble catalytic domain of *E. coli* SPase I even though it lacks the transmembrane domains (Tschantz et al. 1995).

Significant effort has been invested into SPase I inhibitor development. The first reported inhibitor of SPase I was a  $\beta$ -lactam compound (Kuo et al. 1994), and a number of penem type inhibitors have been developed (Allsop et al. 1995, 1996; Barbrook et al. 1996; Black and Bruton 1998; Perry et al. 1995). The first crystal structure of *E. coli* SPase I was solved with the compound allyl (5S,6S)-6-[(R)-acetoxyethyl]-penem-3-carboxylate (Fig. 7.4a) covalently bound to the O $\gamma$  of Ser91, thus proving directly for the first time its role as the nucleophile (Paetzel et al. 1998). The acyl-enzyme inhibitor complex also revealed that the nucleophile of *E. coli* SPase I attacks from the *si*-face of the scissile bond rather than the more commonly observed *re*-face attack. Work has continued on the development of the penem SPase I inhibitors (Harris et al. 2009; Yeh et al. 2018). Lipohexapeptides called arylomycins,

which have antibiotic properties, have been discovered to inhibit SPase I (Fig. 7.4b). These compounds were first isolated from extracts of *Streptomyces* sp. Tu 6075 and have the sequence: D-MeSer, D-Ala, Gly, L-MeHpG, L-Ala, and L-Tyr. The amino acid L-MeHpG is N-methyl-4-hydroxy-phenylglycine (Holtzel et al. 2002; Schimana et al. 2002). The aromatic ring of L-MeHpG is covalently bonded to the aromatic ring of L-Tyr to form a three-residue macrocycle via a 3,3-biaryl bridge. A fatty acid is attached to the amino-terminus. Crystallographic and biophysical analysis reveals that arylomycin binds to *E. coli* SPase I in a non-covalent fashion (Fig. 7.4b) (Paetzel et al. 2004). Analogs of arylomycin inhibitors have also been developed (Dufour et al. 2010; Liu et al. 2011b; Roberts et al. 2007, 2011a, b; Smith et al. 2010, 2011, 2018; Smith and Romesberg 2012). Other reported inhibitors of SPase I include boronic ester-linked macrocyclic lipopeptides (Szalaj et al. 2018) and aldehyde containing lipopeptides (Buzder-Lantos et al. 2009; De Rosa et al. 2017).

The crystal structures, site-directed mutagenesis and kinetic analysis are all consistent with the following proposed catalytic mechanism for *E. coli* SPase I. The c-region of the signal peptide binds within the SPase I substrate binding groove (Michaelis complex) which buries the catalytic residues and likely lowers the  $pK_a$  of the lysine general base, Lys146. Ser91 serves as the nucleophile and is activated by the abstraction of its hydroxyl hydrogen by the deprotonated  $N\ddot{\sigma}$  of the general base Lys146. The Ser279Oy is within hydrogen bonding distance and helps orient the  $N\ddot{\sigma}$  of Lys146 towards Ser91 (Fig. 7.3). The nucleophilic attack from the *si*-face of the scissile carbonyl by the activated Ser91 Oy results in the tetrahedral oxyanion transition state 1. The oxyanion is stabilized via hydrogen bonds to the oxyanion hole (Ser91NH and Ser89OH). The protonated Lys146  $N\ddot{\sigma}$  donates a proton to the main chain nitrogen of the leaving group (P' side of the scissile bond, the mature region of the secretory protein, product 1). The main chain carbonyl carbon of the P1 residue of the signal peptide is then covalently attached via an ester bond to the Ser91 Oy (acyl-enzyme intermediate). A nucleophilic water (a.k.a. deacylating or catalytic water) is activated via the general base Lys146. The structure of *E. coli* SPase I with a free active site revealed a likely candidate for this water (Paetzel et al. 2002) (Fig. 7.3). The hydroxyl is in position to attack the carbonyl carbon of the ester bond. This forms the tetrahedral oxyanion transition state 2, stabilized via hydrogen bonds to the oxyanion hole. This state then leads to the regeneration of the enzyme and release of product 2.

Although *E. coli* SPase I is the most characterized signal peptidase there has been a significant amount of research on other Gram-negative type 1 signal peptidases. Most Gram-negative species have a single SPase I gene that codes for a membrane bound enzyme with two transmembrane segments but there are some exceptions. Photosynthetic bacteria have two types of membranes; the cytoplasmic membrane and the thylakoid membrane. Genomic analysis of the photosynthetic bacteria *Synechocystis* sp. strain PCC 6803 has revealed two SPase I like genes (sll0716 or lepB1 and slr1377 or lepB2) (Zhbanko et al. 2005). Gene knockout analysis was used to show that lepB2 is essential for cell viability and LepB1 is essential for photoautotrophic growth. It will be interesting to look at the relative distribution of these enzymes in the two different membrane systems of this cyanobacterium given that



**Fig. 7.4** Inhibitors of SPase I. **a** The  $\beta$ -lactam type inhibitor, allyl (5S,6S)-6-[(R)-acetoxyethyl]-penem-3-carboxylate (PDB: 1B12). **b** The lipopeptide based inhibitor arylomycin (PDB: 1T7D)

proteomic analysis observes some potential crossover in activity and leaves open the possibility that there maybe other SPase I enzymes. SPase I activity has also been observed from solubilized membranes of the phototrophic  $\alpha$ -purple bacterium *Rhodobacter capsulatus* (Wieseler et al. 1992).

The *Pseudomonas aeruginosa* genome contains the SPase I genes PA0768 and PA1303 (Waite et al. 2012). In vitro assays using FRET-peptide substrates showed that both enzymes are active. PA1303 is smaller than a typical Gram-negative SPase I and is non-essential. PA0768 has more of a typical length for a Gram-negative SPase I and is essential for cell growth. Site-directed mutagenesis suggests that PA1303 plays a role in the quorum-sensing cascade and that PA0768 is the main SPase I in *P. aeruginosa*. *Bradyrhizobium japonicum* is a soil bacterium that fixes nitrogen and is yet another Gram-negative bacterium with two SPase I genes (SipS and SipF) (Bairl and Muller 1998). These enzymes are also different in that they are predicted to have a single amino-terminal transmembrane segment, similar to the Gram-positive SPase I enzymes. The thermophilic cyanobacterium *Phormidium laminosum* also has a SPase I with a predicted single amino-terminal transmembrane segment (Packer et al. 1995). *Legionella pneumophila*, the facultative intracellular Gram-negative bacterium that causes Legionnaires' disease, has a SPase I with a unique sequence feature (Lammertyn et al. 2004). The conserved methionine that immediately follows the nucleophilic serine is a leucine. The structure of *E. coli* SPase showed that this residue is located right behind the Ser/Lys catalytic dyad (Paetzel et al. 1998) (Fig. 7.3).

Other Gram-negative species whose type 1 signal peptidase activity has been confirmed by *in vivo* complementation assays includes: *Azotobacter vinelandii* (Jock et al. 1997), *Bordetella pertussis* (Smith et al. 2000), *Pseudomonas fluorescens* (Black et al. 1992), *Salmonella typhimurium* (van Dijl et al. 1990), *Rickettsia rickettsii* and *Rickettsia typhi* (Rahman et al. 2003).

## Gram-Positive Type 1 Signal Peptidase

Unlike most Gram-negative species that possess a single gene for SPase I, Gram-positive bacteria tend to have multiple genes for SPase I. Sequence alignments reveal that Gram-positive SPase I are shorter in length than the Gram-negative SPase I. They are typically missing part of domain II in their extracytoplasmic region and they tend to have a single transmembrane segment at their amino-terminus rather than the two transmembrane segments normally observed in the Gram-negative SPase I. The best characterized Gram-positive SPase I are those from *Bacillus subtilis* and *Staphylococcus aureus*.

*Bacillus subtilis* SipS was the first Gram-positive SPase I to be characterized in detail (van Dijl et al. 1992). All together, *Bacillus subtilis* has five chromosomally expressed SPase I enzymes (SipS, SipT, SipU, SipV, and SipW) (Bolhuis et al. 1996; Tjalsma et al. 1997) and two plasmid expressed SPase I enzymes (SipP) (Meijer et al. 1995; Tjalsma et al. 1999b). Site-directed mutagenesis experiments are con-

sistent with the SipS utilizing a Ser/Lys catalytic dyad mechanism where Ser43 is the nucleophile and Lys83 serves as the general base. Interestingly it was also found that the mutant M44A showed increased activity (van Dijl et al. 1995). It has been shown that all of the *sip* gene products function as type 1 signal peptidases but only cells lacking both SipS and SipT are not viable (Tjalsma et al. 1998). SipW is very unique in this group of SPase I enzymes in that it has a histidine in place of the general base lysine (Tjalsma et al. 2000). This suggests it is more like the Sec11-like component of the eukaryotic ER signal peptidase complex or the archaeal SPase I (discussed below). SipW is required for processing of the spore-associated protein TasA (Tjalsma et al. 2000). SPase I genes from other *Bacillus* species have been characterized including: *Bacillus amyloliquefaciens* (Chu et al. 2002; Hoang and Hofemeister 1995; van Roosmalen et al. 2001), *Bacillus licheniformis* (Cai et al. 2016) and *Bacillus megaterium* (Malten et al. 2005; Nahrstedt et al. 2004).

*Staphylococcus aureus* has two SPase I-like genes (Cregg et al. 1996). The main SPase I is coded for by the *spsB* gene and is essential. Immediately preceding the *spsB* gene is another SPase I-like gene *spsA* but it lacks the catalytic residues. The nucleophilic serine is replaced by an aspartic acid and the lysine general-base is replaced by a serine. SpsB is involved in quorum sensing. It is responsible for the amino-terminal processing of the autoinducing peptide (AIP) molecule precursor AgrD (Kavanaugh et al. 2007). Kinetic analysis using both preprotein and peptide cleavage assays shows SpsB has a pH optimum around 8 and apparent pK<sub>a</sub> values of 6.6 and 8.7. Curiously, it has been shown that SpsB is not absolutely essential. *S. aureus* is able to survive without SpsB by over-expressing a native gene cassette that encodes a putative ABC transporter. Apparently it compensates for the lack of a SPase I by cleaving a subset of secretory proteins at a site distinct from the SpsB-cleavage site (Craney and Romesberg 2017; Hazenbos et al. 2017; Morisaki et al. 2016).

SpsB is the only SPase I besides *E. coli* SPase I to be crystallographically characterized (Ting et al. 2016). Protein engineering was used to make a crystallizable construct with a peptide substrate tethered for presentation to its binding site (Fig. 7.5a). The catalytic domain of SpsB was fused with *E. coli* maltose binding protein (MBP) to promote solubility, stability, purification and crystallization. The construct included a poly-histidine-affinity tag followed by MBP (residues 33–393), followed by a three-residue linker (Ala-Gly-Ala) and then residues 26–191 of SpsB. The carboxy-terminal residues of SpsB (176–191) that are disordered in the free active site structure were replaced with a Strep-tag II (WSHPQFEK). Four different structures of SpsB were determined; a free active site structure (PDB: 4wvg) with the nucleophilic serine mutated to an alanine (S36A) and three structures with peptides bound and with the wild type residue at position 36. The peptides were tethered covalently to the MBP at an engineered cysteine residue (Q78C) via a thioether linkage. The covalent tether increased the local effective concentration of the peptide and led to high occupancy of the peptide within the binding site and clear electron density for the bound peptide. The peptides (peptide 1: GGGGADHDAHA $\downarrow$ SET, peptide 2: GGGGAVPTAKA $\downarrow$ ASK, and peptide 3: GGGGGAPTAKAPSK) were synthesized with an amino-terminal N-bromo-acetyl moiety that reacted with the S $\gamma$


of the engineered cysteine. The structures of peptide 1 and peptide 2 bound to SpsB (PDB: 4wvh and 4wvi respectively) reveal that the substrate-like peptides have been cleaved at the scissile bond between the P1 and P1' residues resulting in product complexes. The third peptide bound structure (PDB: 4wvj) has a noncleavable P1' proline peptide (peptide 3) showing possible contacts that could be made by the P1'-P3' residues of the substrate in a Michaelis complex. All of these complex structures reveal the methyl group of the P1 alanine pointing into the S1 binding pocket and the methyl group of the P3 alanine pointing into the S3 binding pocket. These structures are consistent with the binding mode previously hypothesized based on *E. coli* SPase I inhibitor complex structures (Liu et al. 2011a; Luo et al. 2009; Paetzel et al. 2002; Paetzel et al. 1998, 2004). SpsB is very similar to domain I of *E. coli* SPase I and the residues that makeup the active site and specificity binding pockets superimpose well. If the engineering of this construct does not interfere with the natural substrate cleavage site presentation, the SPase I-peptide complexes reveal the path that preprotein residues P6 to P3' take along the enzyme surface (Fig. 7.5b).

There have been a number of other characterized Gram-positive type 1 signal peptidase including some from species that are associated with biofilm formation. *Staphylococcus epidermidis* has three SPase I genes (Sip1, Sip2, Sip3). The catalytic activity of Sip2 and Sip3 has been measured using both preprotein and synthetic peptide substrates. Sequence analysis shows that Sip1 does not have a lysine general base (Bockstael et al. 2009). The presence of SPase I paralogs without the full catalytic dyad has been observed in a number of species, such as *S. aureus* SpsA that was mentioned above, but it is not yet clear what role(s) these genes perform. *Streptococcus sanguinis*, contains two SPase I genes; SSA\_0351 and SSA\_0849. SSA\_0351 has been shown to be essential for biofilm formation (Aynapudi et al. 2017). *Actinomyces oris* expresses two SPase I enzymes (LepB1 and LepB2). Mutational analysis is consistent with LepB2 being responsible for processing fimbrial proteins (Siegel et al. 2016).

*Streptococcus pneumoniae* SPase I (the *spi* gene product) has been expressed in *E. coli*, purified, and its activity characterized (Zhang et al. 1997). Site-directed mutagenesis and preprotein processing assays reveal the Ser38 and Lys76 of *S. pneumoniae* SPase I are essential for catalytic activity (Peng et al. 2001). Interestingly, biochemical studies provide evidence that this enzyme undergoes intermolecular self-cleavage that results in loss of activity and that this may play a role in regulation (Zheng et al. 2002).

*Listeria monocytogenes* contains three contiguous SPase I genes in its genome (SipX, SipY and SipZ). Gene knockout analysis has shown that SipZ is the major SPase I involved in the processing of most secretory proteins and that SipX and SipZ are specific for processing proteins related to pathogenicity (Bonnemain et al. 2004; Raynaud and Charbit 2005).

*Streptomyces lividans* contains four different chromosomally encoded SPase I genes (*sipW*, *sipX*, *sipY* and *sipZ*) (Parro et al. 1999). Sequence alignments and functional analysis are consistent with all four of the enzymes having a full set of catalytic residues and all four being able to process preproteins (Geukens et al. 2001b). The first of these genes to be cloned was that of *sipZ* (Parro and Mellado



◀Fig. 7.5 The crystal structure of the catalytic domain of *S. aureus* SPase I (SpsB). **a** Protein engineering was used to make a crystallizable construct of SpsB. Maltose Binding Protein (MBP) was engineered at the amino terminus of SpsB. A strep-affinity-tag replaced the C-terminal residues of SpsB. A series of peptides corresponding to substrate and inhibitor sequences were covalently linked to the MBP via an engineered cysteine, such that they presented the specificity residues to the SpsB substrate-binding groove. **b** A close up view of the SpsB binding groove with the P1' proline peptide (PDB: 4wvj)

1998). Membrane topology analysis shows that SipY has one amino-terminal transmembrane segment and one carboxy-terminal transmembrane segment. Sequence analysis suggests that SipX and SipZ have a similar topology (Geukens et al. 2001a). Kinetic analysis shows that SipW and SipY have a pH optimum of 8–9 whereas SipX and SipZ have a pH optimum of 10–11. All four enzymes show improved activity in the presence of phospholipids (Geukens et al. 2002). Mutagenesis and proteomic analysis is consistent with SipY being the main SPase I for general protein secretion in *S. lividans* (Escutia et al. 2006; Palacin et al. 2002).

## Archaeal Type 1 Signal Peptidase

Genome analysis has shown that archaea possess a gene with sequence similarity to bacterial SPase I, but the lysine general-base that is observed in bacterial SPase I is replaced by a histidine in archaeal SPase I (Eichler 2002). In addition, most archaeal SPase I lack a large region of domain II (Eichler 2002). This suggests that archaeal SPase I maybe similar to the Sec11 component of the signal peptidase complex (SPC) that is present in eukaryotic species (Ng et al. 2007). It is interesting that the bacterial genus *Bacillus* contain SPase I genes that are similar to the eukaryotic or archaeal SPase I homologs. As mentioned above, the *B. subtilis* SipW is a characterized SPase I whose sequence suggests that it utilizes a histidine rather than lysine as its general base (Tjalsma et al. 1998, 2000).


The first characterization of an archaeal type I signal peptidase was that of the methanogenic archaeon *Methanococcus voltae* (Ng and Jarrell 2003). The gene was cloned and expressed in *E. coli* and its activity analyzed using an in vitro assay with a truncated form of *M. voltae* S-layer protein as the substrate. This assay demonstrates that the archaeal SPase I gene product can function without the help of other components. Membrane topology prediction analysis suggests that this enzyme contains an amino-terminal and a carboxy-terminal transmembrane segment. Site directed mutagenesis studies on *M. voltae* SPase I show that Ser52 and His122 are essential residues and that Asp148 may also be essential (Bardy et al. 2005).

The halophilic archaeon *Halofерax volcanii* contains two SPase I genes in its genome (*sec11a* and *sec11b*). Gene deletion studies show that both of these genes are expressed but that only *Sec11b* is essential. Both enzymes were able to cleave preproteins but with different levels of efficiency (Fine et al. 2006). It is not yet clear why some archaea have multiple SPase I paralogs. Of note, genomic analysis sug-

gests that haloarchaea use the Tat pathway rather than the general secretion system for nearly half of their secreted proteins. Since the Tat pathway specializes in the translocation of fully folded proteins, this maybe an adaption to the extreme salt concentrations outside the cell that could prevent proper protein folding. Interestingly, both SPase I enzymes (Sec11a and Sec11b) in *H. volcanii* have an acidic isoelectric point (4.5) consistent with the negative charge seen on most of the *H. volcanii* cell surface proteins. The calculated isoelectric point for most archaeal SPase I are significantly more basic. For example, the isoelectric point of *M. voltae* SPase I is 9.0. Site-directed mutagenesis and in vitro preprotein cleavage assays reveal that the residues Ser72, His137 and Asp187 in *H. volcanii* Sec11b are essential (Fink-Lavi and Eichler 2008).

## Type II Signal Peptidases

SPase II (also called type 2 signal peptidase, prolipoprotein signal peptidase, and LspA) catalyzes the removal of the amino-terminal signal peptide from bacterial proteins that are tethered to the inner membrane by the signal peptide and a diacylglycerol moiety. Many of the insights into the discovery and characterization of SPase II were facilitated by the cyclic pentapeptide (19-membered cyclic depsipeptide) globomycin (Fig. 7.6c). This natural product has four natural amino acid (glycine, L-serine, L-*allo*-isoleucine (2S,3R), L-*allo*-threonine (2S,3S)), N-methyl-L-leucine, and  $\beta$ -hydroxy- $\alpha$ -methyl carboxylic acid ( $\alpha$ -methyl- $\beta$ -hydroxynonanoyl). It is a product of non-ribosomal peptide synthesis in the Gram-positive mycelial bacteria *Actinomycetes*, first isolated in 1978, and shown to have antibacterial activity (Inukai et al. 1978a, b; Nakajima et al. 1978). It was revealed that globomycin's antimicrobial activity is the result of the inhibition of a prolipoprotein processing enzyme which converts prolipoprotein to lipoprotein (Inukai et al. 1978c). This was the first observation of SPase II activity. Globomycin was instrumental in the discovery that the cleavage of the signal peptide by SPase II is essential for the transport of lipoprotein to the outer membrane of Gram-negative bacteria (Hussain et al. 1980). Inhibition of SPase II results in the accumulation of prolipoprotein in the inner membrane which then leads to bacterial cell death (Hussain et al. 1980). This also helped confirm that modification with diacylglycerol occurs before cleavage of the signal peptide. Globomycin is a reversible noncompetitive inhibitor with a  $K_i$  of 36 nM (Dev et al. 1985). Total synthesis and crystallographic analysis led to the relative and absolute configurations of globomycin (Kogen et al. 2000). NMR analysis suggests that globomycin exists as a mixture of two rotational isomers in solution. Synthetic globomycin has the same antimicrobial activity as the naturally purified globomycin and changes to the serine position decreases antimicrobial activity. Solid-phase methods of globomycin synthesis has allowed for further optimization of this inhibitor (Sarabia et al. 2011). Intriguingly, another cyclic secondary metabolite from the Myxobacteria called TA (myxovirescin) also inhibits SPase II (Xiao et al. 2012).



◀Fig. 7.6 The crystal structure of *Pseudomonas aeruginosa* (strain PAO1) SPase II (PDB: 5DIR). **a** The protein fold of SPase II showing the transmembrane segments 1–4 (TM1–4). The  $\beta$ -cradle domain and the PH (periplasmic helix) region are labeled. The proposed catalytic residues Asp124 and Asp143 are labeled. **b** The surface of SPase II reveals three pathways that meet at the proposed position of the P1' cysteine of the prolipoprotein. The proposed pathway for the lipoprotein (mature region of the prolipoprotein) is shaded and labeled, as are the proposed pathways for the signal peptide and the diacylglycerol. The bound lipid used in the crystallization is labeled. The position of the c-region of the signal peptide is proposed based on the position of bound inhibitor globomycin. **c** The molecular structure of SPase II inhibitor globomycin. **d** The active site of SPase II. The proposed catalytic residues Asp124 and Asp143 are within hydrogen bonding distance (dashed lines) to coordinating asparagine residues. The atoms involved in the hydrogen bonding interactions are labeled. The serine residue of globomycin, which mimics the P1 residue of the substrate, is shown in ball-and-stick

SPase II activity has been measured using both *in vivo* and *in vitro* assays (Dev and Ray 1984; Kitamura and Wolan 2018; Yamagata 1983). Recently a high-throughput *in vitro* SPase II activity assay has been designed, allowing for screening of chemical libraries. This has led to the development of inhibitors with nanomolar half-maximal inhibitory concentration values (Kitamura et al. 2018).

The first SPase II to be investigated was the SPase II from *E. coli*. Evidence clearly showed that there existed in *E. coli* a distinct signal peptidase for the processing of lipoproteins (Tokunaga et al. 1982, 1984). Its gene was mapped and sequenced (Regue et al. 1984; Tokunaga et al. 1984) and the enzyme-fusion technique was used to determine its membrane topology. This analysis suggested that *E. coli* SPase II has four transmembrane segments with both the amino-terminus and the carboxy-terminus residing in the cytoplasm (Munroa et al. 1991). SPase II genes from other Gram-negative bacterial have been characterized including: *Enterobacter aerogenes* (Isaki et al. 1990), *Legionella pneumophila* (Geukens et al. 2006), *Myxococcus xanthus* (Paitan et al. 1999), and *Rickettsia typhi* (Rahman et al. 2007), and *Pseudomonas aeruginosa* (Vogeley et al. 2016).

Gram-positive SPase II enzymes that have been characterized include: *Bacillus subtilis* (Pragai et al. 1997; Tjalsma et al. 1999a, c), *Staphylococcus carnosus* (Witte and Gotz 1995), *Streptococcus pneumonia* (Khandavilli et al. 2008), *Streptococcus suis* (De Greeff et al. 2003), *Streptomyces coelicolor* (Munnoch et al. 2016), and *Streptomyces lividans* (Gullon et al. 2013). Sequence alignments and site-directed mutagenesis in *B. subtilis* SPase II suggest that SPase II is a unique aspartic protease (Tjalsma et al. 1999c).

One structure of a SPase II enzyme is available (Vogeley et al. 2016). LspA from *Pseudomonas aeruginosa* (strain PAO1) was crystallized using the *in meso* (lipid cubic phase) method (Caffrey 2015). The structure is refined to 2.8 Å resolution. The crystallization conditions were at pH 5.6–6.0 and included MES buffer, PEG400, ammonium phosphate, and monoolein (monoacylglycerol, 9.9 MAG, 1-(9Z-octadecenoyl)-rac-glycerol). The enzyme is 169 residues in length (UniProt: Q9HVM5, molecular mass 18,997 Da, isoelectric point 8.0). The crystal structure has clear electron density for residues 2–158 (for chain A, the most ordered of the

four molecules in the asymmetry unit). Structural analysis suggests SPase II is a monomer.

The crystal structure of SPase II from *Pseudomonas aeruginosa* showed there are four transmembrane segments with a topology that places both the amino- and carboxy-termini in the cytoplasm (TM1: residues 9–34, TM2: residues 68–90, TM3: residues 95–119, and TM4: residues 140–158) (Fig. 7.6a). This topology is consistent with the gene-fusion topology analysis performed on the *E. coli* SPase II homolog (Munoa et al. 1991). The first three residues of TM1 are in the  $3_{10}$ -helical conformation. There is also a small periplasmic domain that is made up of a four-stranded antiparallel  $\beta$ -sheet ( $\beta$ 1: residues 40–43,  $\beta$ 2: residues 46–54,  $\beta$ 3: residues 122–130,  $\beta$ 4: residues 134–136). Because of its shape, this domain is referred to as the  $\beta$ -cradle. There is also a loop region with a single  $3_{10}$ -helical turn (residues 60–62), which is referred to as the periplasmic helix (PH). The  $\beta$ -cradle and PH are amphipathic in nature and reside on the periplasmic region of the protein, along the surface of the periplasmic side of the inner membrane lipid bilayer, approximately perpendicular to the orientation of the TM helices. The first two strands of the  $\beta$ -sheet and the PH are an insertion between TM1 and 2. The last 2  $\beta$ -stands within the  $\beta$ -sheet are an insertion between TM3 and 4. The secondary structure assignments discussed here were assigned using the program PROMOTIF (Hutchinson and Thornton 1996).

The SPase II structure was cocrystallized with globomycin. This allowed for the clear interpretation of the substrate binding groove and the catalytic active site. The substrate-binding groove is located at the periplasmic end of TM2, 3 and 4. The residues that have direct interactions with the inhibitor, and therefore likely with the prolipoprotein substrate as well, include residues that reside on TM3 such as Arg116 and Asn112. Interactions also come from Asn140 and Asp143, residing on TM4. Contacts are made from Asp124 found on the third  $\beta$ -strand within the  $\beta$ -sheet. The residues Leu-Ile-Ser of globomycin likely fit into the substrate-binding groove of SPase II in a similar fashion to the lipobox residues in the prolipoprotein. The residues surrounding the bound inhibitor correspond to the residues that are most conserved in SPase II.

Modeling and molecular dynamics simulations suggests that the  $\text{C}\alpha$  atom of the P1' cysteine within the prolipoprotein substrate sits at a three-way crossroad of three substrate binding surfaces on the surface of LspA (Fig. 7.6b). The periplasmic  $\beta$ -cradle and the PH-loop region form a groove where the mature region of the lipoprotein would be directed. A second groove is formed by the periplasmic  $\beta$ -cradle and TM4. The side chain of the P1' cysteine could fit in this groove and the thioether linkage to diacylglycerol would direct the fatty acids to lay across the surface of TM4. A binding surface is formed from TM helices 2, 3 and 4. This creates a long surface for the signal peptide to bind. The surface complementarity between this enzyme and its unique substrate allows for LspA to recognize and cleave a broad range of prolipoproteins.

The clues provided by the inhibitor complex allowed for a hypothetical Michaelis complex to be modeled. This model in turn suggested the identity of the residues involved in the catalytic mechanism. The most likely residues are Asp124 and Asp143 (Fig. 7.6a, d). Asp124 resides on the amino-terminal end of  $\beta$ -strand 3 ( $\beta$ 3) and Asp143 resides on the amino-terminal end of TM4. In the globomycin-SPase II complex the globomycin serine hydroxyl group hydrogen bonds to both of the proposed catalytic residues. Sequence alignments show 14 strictly conserved residues: Asp23, Lys27, Asn54, Gly56, Gly108, Ala109, Asn112, Arg116, Val122, Asp124, Phe139, Asn140, Ala142, and Asp143. Most of these residues are located near the active site. Site-directed mutagenesis was consistent with Asp124 and Asp143 being essential residues. This suggests that these residues likely play a direct role in catalysis similar to the classic aspartic protease mechanism (Rawlings and Barrett 2013; Wlodawer et al. 2013). A constellation of asparagine residues helps to coordinate and orient the proposed catalytic residues (Fig. 7.6d). Asp143 O<sub>81</sub> is hydrogen bonded to Asn112 N<sub>82</sub> (3.0 Å). Asp124 O<sub>82</sub> is hydrogen bonded to Asn54 N<sub>82</sub> (3.4 Å) and Asp124 O<sub>81</sub> is hydrogen bonded to Asn140 N<sub>82</sub> (3.2 Å). In the future, it will be helpful to see a structure of this enzyme with a free active site; this may reveal the coordination geometry for the catalytic water. It is likely that the bound globomycin has displaced the catalytic water. If the c-region of the prolipoprotein substrate lays within the binding site of SPase II in a similar orientation to that of the cyclic peptide globomycin, then the structure suggests that the nucleophilic water attacks from the *si*-face of the substrate's scissile carbonyl. The hydroxyl oxygen of the serine within the bound globomycin sits adjacent to the two proposed catalytic carboxylate groups of Asp124 and Asp143. The hydroxyl oxygen is closer to Asp143 O<sub>82</sub> (2.4 Å) than it is to Asp 124 O<sub>81</sub> (2.9 Å). If the globomycin serine hydroxyl is mimicking one of the hydroxyls of the *gem*-diol transition state, then it is possible that the Asp143 is stabilizing the transition state via a low barrier hydrogen bond as has been proposed in some aspartic proteases (Wlodawer et al. 2013). A full stereo-electronic understanding of the SPase II mechanism awaits structural analysis at higher resolution.

## Other Signal Peptide Cleaving Enzymes

Although they have not been covered in this chapter, there are a number of other bacterial peptidases associated with protein secretion such as those involved in prepilin processing (Dupuy et al. 2013) and hydrolysis of signal peptides (Dalbey and Wang 2013).

**Acknowledgements** The author would like to thank Dr. Andreas Kuhn for the opportunity to contribute to this book.

## References

Allsop AE, Brooks G, Bruton G, Coulton S, Edwards PD, Hatton IK, Kaura AC, McLean SD, Pearson ND, Smale TC, Southgate R (1995) Penem inhibitors of bacterial signal peptidase. *Biorg Medic Chem Lett* 5:443–448

Allsop A, Brooks G, Edwards PD, Kaura AC, Southgate R (1996) Inhibitors of bacterial signal peptidase: a series of 6-(substituted oxyethyl)penems. *J Antibiot (Tokyo)* 49:921–928

Armbruster KM, Meredith TC (2018) Enrichment of bacterial lipoproteins and preparation of N-terminal lipopeptides for structural determination by mass spectrometry. *J Vis Exp: JoVE*

Aynapudi J, El-Rami F, Ge X, Stone V, Zhu B, Kitten T, Xu P (2017) Involvement of signal peptidase I in *Streptococcus sanguinis* biofilm formation. *Microbiology* 163:1306–1318

Babu MM, Priya ML, Selvan AT, Madera M, Gough J, Aravind L, Sankaran K (2006) A database of bacterial lipoproteins (DOLOP) with functional assignments to predicted lipoproteins. *J Bacteriol* 188:2761–2773

Bagos PG, Tsirigos KD, Plessas SK, Liakopoulos TD, Hamodrakas SJ (2009) Prediction of signal peptides in archaea. *Protein Eng Des Sel* 22:27–35

Bairl A, Muller P (1998) A second gene for type I signal peptidase in *Bradyrhizobium japonicum*, *sipF*, is located near genes involved in RNA processing and cell division. *Mol Gen Genet* 260:346–356

Barbrook AC, Packer JC, Howe CJ (1996) Inhibition by penem of processing peptidases from cyanobacteria and chloroplast thylakoids. *FEBS Lett* 398:198–200

Bardy SL, Eichler J, Jarrell KF (2003) Archaeal signal peptides—a comparative survey at the genome level. *Protein Sci* 12:1833–1843

Bardy SL, Ng SY, Carnegie DS, Jarrell KF (2005) Site-directed mutagenesis analysis of amino acids critical for activity of the type I signal peptidase of the archaeon *Methanococcus voltae*. *J Bacteriol* 187:1188–1191

Bechinger B, Giersch LM, Montal M, Zasloff M, Opella SJ (1996) Orientations of helical peptides in membrane bilayers by solid state NMR spectroscopy. *Solid State Nucl Magn Reson* 7:185–191

Berger A, Schechter I (1970) Mapping the active site of papain with the aid of peptide substrates and inhibitors. *Philos Trans R Soc Lond B Biol Sci* 257:249–264

Bilgin N, Lee JI, Zhu HY, Dalbey R, von Heijne G (1990) Mapping of catalytically important domains in *Escherichia coli* leader peptidase. *EMBO J* 9:2717–2722

Black MT (1993) Evidence that the catalytic activity of prokaryote leader peptidase depends upon the operation of a serine-lysine catalytic dyad. *J Bacteriol* 175:4957–4961

Black MT, Bruton G (1998) Inhibitors of bacterial signal peptidases. *Curr Pharm Des* 4:133–154

Black MT, Munn JG, Allsop AE (1992) On the catalytic mechanism of prokaryotic leader peptidase 1. *Biochem J* 282:539–543

Blobel G, Dobberstein B (1975a) Transfer of proteins across membranes. I. Presence of proteolytically processed and unprocessed nascent immunoglobulin light chains on membrane-bound ribosomes of murine myeloma. *J Cell Biol* 67:835–851

Blobel G, Dobberstein B (1975b) Transfer of proteins across membranes. II. Reconstitution of functional rough microsomes from heterologous components. *J Cell Biol* 67:852–862

Bochtler M, Mizgalska D, Veillard F, Nowak ML, Houston J, Veith P, Reynolds EC, Potempa J (2018) The Bacteroidetes Q-Rule: pyroglutamate in signal peptidase I substrates. *Front Microbiol* 9:230

Bockstael K, Geukens N, Rao CV, Herdewijn P, Anne J, Van Aerschot A (2009) An easy and fast method for the evaluation of *Staphylococcus epidermidis* type I signal peptidase inhibitors. *J Microbiol Methods* 78:231–237

Bolhuis A, Sorokin A, Azevedo V, Ehrlich SD, Braun PG, de Jong A, Venema G, Bron S, van Dijken JM (1996) *Bacillus subtilis* can modulate its capacity and specificity for protein secretion through temporally controlled expression of the *sipS* gene for signal peptidase I. *Mol Microbiol* 22:605–618

Bonnemain C, Raynaud C, Reglier-Poupet H, Dubail I, Frehel C, Lety MA, Berche P, Charbit A (2004) Differential roles of multiple signal peptidases in the virulence of *Listeria monocytogenes*. *Mol Microbiol* 51:1251–1266

Buddelmeijer N, Young R (2010) The essential *Escherichia coli* apolipoprotein N-acyltransferase (Lnt) exists as an extracytoplasmic thioester acyl-enzyme intermediate. *Biochemistry* 49:341–346

Buzder-Lantos P, Bockstaal K, Anne J, Herdewijn P (2009) Substrate based peptide aldehyde inhibits bacterial type I signal peptidase. *Bioorg Med Chem Lett* 19:2880–2883

Caffrey M (2015) A comprehensive review of the lipid cubic phase or in meso method for crystallizing membrane and soluble proteins and complexes. *Acta Crystallogr Sect F, Struct Biol Commun* 71:3–18

Cai D, Wei X, Qiu Y, Chen Y, Chen J, Wen Z, Chen S (2016) High-level expression of nattokinase in *Bacillus licheniformis* by manipulating signal peptide and signal peptidase. *J Appl Microbiol* 121:704–712

Carlos JL, Klenotic PA, Paetzel M, Strynadka NC, Dalbey RE (2000) Mutational evidence of transition state stabilization by serine 88 in *Escherichia coli* type I signal peptidase. *Biochemistry* 39:7276–7283

Chang CN, Blobel G, Model P (1978) Detection of prokaryotic signal peptidase in an *Escherichia coli* membrane fraction: endoproteolytic cleavage of nascent f1 pre-coat protein. *Proc Natl Acad Sci USA* 75:361–365

Chatzi KE, Sardis MF, Karamanou S, Economou A (2013) Breaking on through to the other side: protein export through the bacterial Sec system. *Biochem J* 449:25–37

Chimalapati S, Sankaran K, Brown JS (2013) Chapter 62—signal peptidase II. In: *Handbook of proteolytic enzymes*. Academic Press, pp 258–261

Choo KH, Tan TW, Ranganathan S (2009) A comprehensive assessment of N-terminal signal peptides prediction methods. *BMC Bioinform* 10(Suppl 15):S2

Chu HH, Hoang V, Kreutzmann P, Hofemeister B, Melzer M, Hofemeister J (2002) Identification and properties of type I-signal peptidases of *Bacillus amyloliquefaciens*. *Eur J Biochem* 269:458–469

Craney A, Romesberg FE (2017) Stable signal peptides and the response to secretion stress in *staphylococcus aureus*. *mBio* 8

Cregg KM, Wilding I, Black MT (1996) Molecular cloning and expression of the *spsB* gene encoding an essential type I signal peptidase from *Staphylococcus aureus*. *J Bacteriol* 178:5712–5718

Dalbey RE, Wang P (2013) Chapter 798—signal peptide peptidase A (Prokaryotes). In: *Handbook of proteolytic enzymes*. Academic Press, pp 3611–3613

Dalbey RE, Wickner W (1985) Leader peptidase catalyzes the release of exported proteins from the outer surface of the *Escherichia coli* plasma membrane. *J Biol Chem* 260:15925–15931

Date T (1983) Demonstration by a novel genetic technique that leader peptidase is an essential enzyme of *Escherichia coli*. *J Bacteriol* 154:76–83

De Bona P, Deshmukh L, Gorbatyuk V, Vinogradova O, Kendall DA (2012) Structural studies of a signal peptide in complex with signal peptidase I cytoplasmic domain: the stabilizing effect of membrane-mimetics on the acquired fold. *Proteins* 80:807–817

De Greeff A, Hamilton A, Sutcliffe IC, Buys H, Van Alphen L, Smith HE (2003) Lipoprotein signal peptidase of *Streptococcus suis* serotype 2. *Microbiology* 149:1399–1407

De Rosa M, Lu L, Zamaratski E, Szalaj N, Cao S, Wadensten H, Lenhammar L, Gising J, Roos AK, Huseby DL et al (2017) Design, synthesis and in vitro biological evaluation of oligopeptides targeting *E. coli* type I signal peptidase (LepB). *Bioorg Med Chem* 25:897–911

Dev IK, Ray PH (1984) Rapid assay and purification of a unique signal peptidase that processes the prolipoprotein from *Escherichia coli* B. *J Biol Chem* 259:11114–11120

Dev IK, Harvey RJ, Ray PH (1985) Inhibition of prolipoprotein signal peptidase by globomycin. *J Biol Chem* 260:5891–5894

Driessens AJ, Nouwen N (2008) Protein translocation across the bacterial cytoplasmic membrane. *Annu Rev Biochem* 77:643–667

Dufour J, Neuville L, Zhu J (2010) Intramolecular Suzuki-Miyaura reaction for the total synthesis of signal peptidase inhibitors, arylomycins A(2) and B(2). *Chemistry* 16:10523–10534

Dupuy B, Deghmane A-E, Taha M-K (2013) Chapter 63—type IV prepilin peptidase. In: *Handbook of proteolytic enzymes*. Academic Press, pp 261–265

Eichler J (2002) Archaeal signal peptidases from the genus *Thermoplasma*: structural and mechanistic hybrids of the bacterial and eukaryal enzymes. *J Mol Evol* 54:411–415

Ekici OD, Karla A, Paetzel M, Lively MO, Pei D, Dalbey RE (2007) Altered-3 substrate specificity of *Escherichia coli* signal peptidase 1 mutants as revealed by screening a combinatorial peptide library. *J Biol Chem* 282:417–425

Escutia MR, Val G, Palacin A, Geukens N, Anne J, Mellado RP (2006) Compensatory effect of the minor *Streptomyces lividans* type I signal peptidases on the SipY major signal peptidase deficiency as determined by extracellular proteome analysis. *Proteomics* 6:4137–4146

Fine A, Irihimovich V, Dahan I, Konrad Z, Eichler J (2006) Cloning, expression, and purification of functional Sec11a and Sec11b, type I signal peptidases of the archaeon *Haloferax volcanii*. *J Bacteriol* 188:1911–1919

Fink-Lavi E, Eichler J (2008) Identification of residues essential for the catalytic activity of Sec11b, one of the two type I signal peptidases of *Haloferax volcanii*. *FEMS Microbiol Lett* 278:257–260

Freudl R (2018) Signal peptides for recombinant protein secretion in bacterial expression systems. *Microb Cell Fact* 17:52

Geukens N, Lammertyn E, Van Mellaert L, Schacht S, Schaeirlaekens K, Parro V, Bron S, Engelborghs Y, Mellado RP, Anne J (2001a) Membrane topology of the *Streptomyces lividans* type I signal peptidases. *J Bacteriol* 183:4752–4760

Geukens N, Parro V, Rivas LA, Mellado RP, Anne J (2001b) Functional analysis of the *Streptomyces lividans* type I signal peptidases. *Arch Microbiol* 176:377–380

Geukens N, Lammertyn E, Van Mellaert L, Engelborghs Y, Mellado RP, Anne J (2002) Physical requirements for in vitro processing of the *Streptomyces lividans* signal peptidases. *J Biotechnol* 96:79–91

Geukens N, De Buck E, Meyen E, Maes L, Vranckx L, Van Mellaert L, Anne J, Lammertyn E (2006) The type II signal peptidase of *Legionella pneumophila*. *Res Microbiol* 157:836–841

Ghahremanifard P, Rezaeinezhad N, Rigi G, Ramezani F, Ahmadian G (2018) Designing a novel signal sequence for efficient secretion of *Candida antarctica* lipase B in *E. coli*: the molecular dynamic simulation, codon optimization and statistical analysis approach. *Int J Biol Macromol* 119:291–305

Gullon S, Arranz EI, Mellado RP (2013) Transcriptional characterisation of the negative effect exerted by a deficiency in type II signal peptidase on extracellular protein secretion in *Streptomyces lividans*. *Appl Microbiol Biotechnol* 97:10069–10080

Harris DA, Powers ME, Romesberg FE (2009) Synthesis and biological evaluation of penem inhibitors of bacterial signal peptidase. *Bioorg Med Chem Lett* 19:3787–3790

Hazenbos WL, Skippington E, Tan MW (2017) *Staphylococcus aureus* type I signal peptidase: essential or not essential, that's the question. *Microbial cell* 4:108–111

Hillmann F, Argentini M, Buddelmeijer N (2011) Kinetics and phospholipid specificity of apolipoprotein N-acyltransferase. *J Biol Chem* 286:27936–27946

Hoang V, Hofemeister J (1995) *Bacillus amyloliquefaciens* possesses a second type I signal peptidase with extensive sequence similarity to other *Bacillus* SPases. *Biochim Biophys Acta* 1269:64–68

Holtzel A, Schmid DG, Nicholson GJ, Stevanovic S, Schimana J, Gebhardt K, Fiedler HP, Jung G (2002) Arylomycins A and B, new biaryl-bridged lipopeptide antibiotics produced by *Streptomyces* sp. Tu 6075. II. Structure elucidation. *J Antibiot (Tokyo)* 55:571–577

Hussain M, Ichihara S, Mizushima S (1980) Accumulation of glyceride-containing precursor of the outer membrane lipoprotein in the cytoplasmic membrane of *Escherichia coli* treated with globomycin. *J Biol Chem* 255:3707–3712

Hutchings MI, Palmer T, Harrington DJ, Sutcliffe IC (2009) Lipoprotein biogenesis in Gram-positive bacteria: knowing when to hold 'em, knowing when to fold 'em. *Trends Microbiol* 17:13–21

Hutchinson EG, Thornton JM (1996) PROMOTIF—a program to identify and analyze structural motifs in proteins. *Protein Sci* 5:212–220

Inouye S, Franceschini T, Sato M, Itakura K, Inouye M (1983) Prolipoprotein signal peptidase of *Escherichia coli* requires a cysteine residue at the cleavage site. *EMBO J* 2:87–91

Inukai M, Enokita R, Torikata A, Nakahara M, Iwado S, Arai M (1978a) Globomycin, a new peptide antibiotic with spheroplast-forming activity. I. Taxonomy of producing organisms and fermentation. *J Antibiot (Tokyo)* 31:410–420

Inukai M, Nakajima M, Osawa M, Haneishi T, Arai M (1978b) Globomycin, a new peptide antibiotic with spheroplast-forming activity. II. Isolation and physico-chemical and biological characterization. *J Antibiot (Tokyo)* 31:421–425

Inukai M, Takeuchi M, Shimizu K, Arai M (1978c) Mechanism of action of globomycin. *J Antibiot (Tokyo)* 31:1203–1205

Isaki L, Kawakami M, Beers R, Hom R, Wu HC (1990) Cloning and nucleotide sequence of the *Enterobacter aerogenes* signal peptidase II (lsp) gene. *J Bacteriol* 172:469–472

Jock CA, Pulakat L, Lee S, Gavini N (1997) Nucleotide sequence and genetic complementation analysis of *lep* from *Azotobacter vinelandii*. *Biochem Biophys Res Commun* 239:393–400

Juncker AS, Willenbrock H, Von Heijne G, Brunak S, Nielsen H, Krogh A (2003) Prediction of lipoprotein signal peptides in Gram-negative bacteria. *Protein Sci* 12:1652–1662

Kaderbhai NN, Harding V, Kaderbhai MA (2008) Signal peptidase I-mediated processing of an engineered mammalian cytochrome b(5) precursor is an exocytosomal post-translational event in *Escherichia coli*. *Mol Membr Biol* 25:388–399

Karla A, Lively MO, Paetzel M, Dalbey R (2005) The identification of residues that control signal peptidase cleavage fidelity and substrate specificity. *J Biol Chem* 280:6731–6741

Kavanaugh JS, Thoendel M, Horswill AR (2007) A role for type I signal peptidase in *Staphylococcus aureus* quorum sensing. *Mol Microbiol* 65:780–798

Khandavilli S, Homer KA, Yuste J, Basavanna S, Mitchell T, Brown JS (2008) Maturation of *Streptococcus pneumoniae* lipoproteins by a type II signal peptidase is required for ABC transporter function and full virulence. *Mol Microbiol* 67:541–557

Kim YT, Muramatsu T, Takahashi K (1995a) Identification of Trp300 as an important residue for *Escherichia coli* leader peptidase activity. *Eur J Biochem* 234:358–362

Kim YT, Muramatsu T, Takahashi K (1995b) Leader peptidase from *Escherichia coli*: overexpression, characterization, and inactivation by modification of tryptophan residues 300 and 310 with N-bromosuccinimide. *J Biochem* 117:535–544

Kitamura S, Wolan DW (2018) Probing substrate recognition of bacterial lipoprotein signal peptidase using FRET reporters. *FEBS Lett* 592:2289–2296

Kitamura S, Owensby A, Wall D, Wolan DW (2018) Lipoprotein signal peptidase inhibitors with antibiotic properties identified through design of a robust in vitro HT platform. *Cell Chem Biol* 25(301–308):e312

Klenotic PA, Carlos JL, Samuelson JC, Schuenemann TA, Tschantz WR, Paetzel M, Strynadka NC, Dalbey RE (2000) The role of the conserved box E residues in the active site of the *Escherichia coli* type I signal peptidase. *J Biol Chem* 275:6490–6498

Kogen H, Kiho T, Nakayama M, Furukawa Y, Kinoshita T, Inukai M (2000) Crystal structure and total synthesis of globomycin: establishment of relative and absolute configurations. *J Am Chem Soc* 122:10214–10215

Konovalova A, Silhavy TJ (2015) Outer membrane lipoprotein biogenesis: lol is not the end. *Philos Trans R Soc Lond B Biol Sci* 370

Kovacs-Simon A, Titball RW, Michell SL (2011) Lipoproteins of bacterial pathogens. *Infect Immun* 79:548–561

Kuo D, Weidner J, Griffin P, Shah SK, Knight WB (1994) Determination of the kinetic parameters of *Escherichia coli* leader peptidase activity using a continuous assay: the pH dependence and time-dependent inhibition by beta-lactams are consistent with a novel serine protease mechanism. *Biochemistry* 33:8347–8354

Lammertyn E, Van Mellaert L, Meyen E, Lebeau I, De Buck E, Anne J, Geukens N (2004) Molecular and functional characterization of type I signal peptidase from *Legionella pneumophila*. *Microbiology* 150:1475–1483

Leversen NA, de Souza GA, Malen H, Prasad S, Jonassen I, Wiker HG (2009) Evaluation of signal peptide prediction algorithms for identification of mycobacterial signal peptides using sequence data from proteomic methods. *Microbiology* 155:2375–2383

Liu J, Luo C, Smith PA, Chin JK, Page MG, Paetzel M, Romesberg FE (2011a) Synthesis and characterization of the arylomycin lipoglycopeptide antibiotics and the crystallographic analysis of their complex with signal peptidase. *J Am Chem Soc* 133:17869–17877

Liu WT, Kersten RD, Yang YL, Moore BS, Dorrestein PC (2011b) Imaging mass spectrometry and genome mining via short sequence tagging identified the anti-infective agent arylomycin in *Streptomyces roseosporus*. *J Am Chem Soc* 133:18010–18013

LoVullo ED, Wright LF, Isabella V, Huntley JF, Pavelka MS Jr (2015) Revisiting the Gram-negative lipoprotein paradigm. *J Bacteriol* 197:1705–1715

Low KO, Muhammad Mahadi N, Md Illias R (2013) Optimisation of signal peptide for recombinant protein secretion in bacterial hosts. *Appl Microbiol Biotechnol* 97:3811–3826

Luke I, Handford JI, Palmer T, Sargent F (2009) Proteolytic processing of *Escherichia coli* twin-arginine signal peptides by LepB. *Arch Microbiol* 191:919–925

Luo C, Roussel P, Dreier J, Page MG, Paetzel M (2009) Crystallographic analysis of bacterial signal peptidase in ternary complex with arylomycin A2 and a beta-sultam inhibitor. *Biochemistry* 48:8976–8984

Madan Babu M, Sankaran K (2002) DOLOP—database of bacterial lipoproteins. *Bioinformatics* 18:641–643

Malten M, Nahrstedt H, Meinhardt F, Jahn D (2005) Coexpression of the type I signal peptidase gene *sipM* increases recombinant protein production and export in *Bacillus megaterium* MS941. *Biotechnol Bioeng* 91:616–621

Mao G, Zhao Y, Kang X, Li Z, Zhang Y, Wang X, Sun F, Sankaran K, Zhang XC (2016) Crystal structure of *E. coli* lipoprotein diacylglycerol transferase. *Nat Commun* 7:10198

McKnight CJ, Rafalski M, Giersch LM (1991a) Fluorescence analysis of tryptophan-containing variants of the LamB signal sequence upon insertion into a lipid bilayer. *Biochemistry* 30:6241–6246

McKnight CJ, Stradley SJ, Jones JD, Giersch LM (1991b) Conformational and membrane-binding properties of a signal sequence are largely unaltered by its adjacent mature region. *Proc Natl Acad Sci USA* 88:5799–5803

Meijer WJ, de Jong A, Bea G, Wisman A, Tjalsma H, Venema G, Bron S, van Dijl JM (1995) The endogenous *Bacillus subtilis* (natto) plasmids pTA1015 and pTA1040 contain signal peptidase-encoding genes: identification of a new structural module on cryptic plasmids. *Mol Microbiol* 17:621–631

Milstein C, Brownlee GG, Harrison TM, Mathews MB (1972) A possible precursor of immunoglobulin light chains. *Nat New Biol* 239:117–120

Molino JVD, de Carvalho JCM, Mayfield SP (2018) Comparison of secretory signal peptides for heterologous protein expression in microalgae: expanding the secretion portfolio for *Chlamydomonas reinhardtii*. *PLoS ONE* 13:e0192433

Moore KE, Miura S (1987) A small hydrophobic domain anchors leader peptidase to the cytoplasmic membrane of *Escherichia coli*. *J Biol Chem* 262:8806–8813

Morisaki JH, Smith PA, Date SV, Kajihara KK, Truong CL, Modrusan Z, Yan D, Kang J, Xu M, Shah IM et al (2016) A putative bacterial ABC transporter circumvents the essentiality of signal peptidase. *mBio* 7

Muhammad MA, Falak S, Rashid N, Gardner QA, Ahmad N, Imanaka T, Akhtar M (2017) *Escherichia coli* signal peptidase recognizes and cleaves archaeal signal sequence. *Biochemistry (Mosc)* 82:821–825

Munnoch JT, Widdick DA, Chandra G, Sutcliffe IC, Palmer T, Hutchings MI (2016) Cosmid based mutagenesis causes genetic instability in *Streptomyces coelicolor*, as shown by targeting of the lipoprotein signal peptidase gene. *Sci Rep* 6:29495

Munoz FJ, Miller KW, Beers R, Graham M, Wu HC (1991) Membrane topology of *Escherichia coli* prolipoprotein signal peptidase (signal peptidase II). *J Biol Chem* 266:17667–17672

Musial-Siwek M, Kendall DA, Yeagle PL (2008a) Solution NMR of signal peptidase, a membrane protein. *Biochim Biophys Acta* 1778:937–944

Musial-Siwek M, Yeagle PL, Kendall DA (2008b) A small subset of signal peptidase residues are perturbed by signal peptide binding. *Chem Biol Drug Des* 72:140–146

Nahrstedt H, Wittchen K, Rachman MA, Meinhardt F (2004) Identification and functional characterization of a type I signal peptidase gene of *Bacillus megaterium* DSM319. *Appl Microbiol Biotechnol* 64:243–249

Nakajima M, Inukai M, Haneishi T, Terahara A, Arai M, Kinoshita T, Tamura C (1978) Globomycin, a new peptide antibiotic with spheroplast-forming activity. III. Structural determination of globomycin. *J Antibiot (Tokyo)* 31:426–432

Nakayama H, Kurokawa K, Lee BL (2012) Lipoproteins in bacteria: structures and biosynthetic pathways. *FEBS J* 279:4247–4268

Narita SI, Tokuda H (2017) Bacterial lipoproteins; biogenesis, sorting and quality control. *Biochim Biophys Acta* 1862:1414–1423

Ng SY, Jarrell KF (2003) Cloning and characterization of archaeal type I signal peptidase from *Methanococcus voltae*. *J Bacteriol* 185:5936–5942

Ng SY, Chaban B, VanDyke DJ, Jarrell KF (2007) Archaeal signal peptidases. *Microbiology* 153:305–314

Nguyen MT, Gotz F (2016) Lipoproteins of Gram-positive bacteria: Key players in the immune response and virulence. *Microbiol Mol Biol Rev* 80:891–903

Nielsen H, Engelbrecht J, Brunak S, von Heijne G (1997a) Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. *Protein Eng* 10:1–6

Nielsen H, Engelbrecht J, Brunak S, von Heijne G (1997b) A neural network method for identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. *Int J Neural Syst* 8:581–599

Noland CL, Kattke MD, Diao J, Gloor SL, Pantua H, Reichelt M, Katakam AK, Yan D, Kang J, Zilberleyb I et al (2017) Structural insights into lipoprotein N-acylation by *Escherichia coli* apolipoprotein N-acyltransferase. *Proc Natl Acad Sci USA* 114:E6044–E6053

Nyathi Y, Wilkinson BM, Pool MR (2013) Co-translational targeting and translocation of proteins to the endoplasmic reticulum. *Biochim Biophys Acta* 1833:2392–2402

Owji H, Nezafat N, Negahdaripour M, Hajiebrahimi A, Ghasemi Y (2018) A comprehensive review of signal peptides: structure, roles, and applications. *Eur J Cell Biol* 97:422–441

Packer JC, Andre D, Howe CJ (1995) Cloning and sequence analysis of a signal peptidase I from the thermophilic cyanobacterium *Phormidium laminosum*. *Plant Mol Biol* 27:199–204

Paetzel M, Strynadka NC (1999) Common protein architecture and binding sites in proteases utilizing a Ser/Lys dyad mechanism. *Protein Sci* 8:2533–2536

Paetzel M, Chernaia M, Strynadka N, Tschantz W, Cao G, Dalbey RE, James MN (1995) Crystallization of a soluble, catalytically active form of *Escherichia coli* leader peptidase. *Proteins* 23:122–125

Paetzel M, Strynadka NC, Tschantz WR, Casareno R, Bullinger PR, Dalbey RE (1997) Use of site-directed chemical modification to study an essential lysine in *Escherichia coli* leader peptidase. *J Biol Chem* 272:9994–10003

Paetzel M, Dalbey RE, Strynadka NC (1998) Crystal structure of a bacterial signal peptidase in complex with a beta-lactam inhibitor. *Nature* 396:186–190

Paetzel M, Dalbey RE, Strynadka NC (2002) Crystal structure of a bacterial signal peptidase apoenzyme: implications for signal peptide binding and the Ser-Lys dyad mechanism. *J Biol Chem* 277:9512–9519

Paetzel M, Goodall JJ, Kania M, Dalbey RE, Page MG (2004) Crystallographic and biophysical analysis of a bacterial signal peptidase in complex with a lipopeptide-based inhibitor. *J Biol Chem* 279:30781–30790

Paitan Y, Orr E, Ron EZ, Rosenberg E (1999) A nonessential signal peptidase II (Lsp) of *Myxococcus xanthus* might be involved in biosynthesis of the polyketide antibiotic TA. *J Bacteriol* 181:5644–5651

Palacin A, Parro V, Geukens N, Anne J, Mellado RP (2002) SipY is the *Streptomyces lividans* type I signal peptidase exerting a major effect on protein secretion. *J Bacteriol* 184:4875–4880

Parro V, Mellado RP (1998) A new signal peptidase gene from *Streptomyces lividans* TK21. *DNA Seq* 9:71–77

Parro V, Schacht S, Anne J, Mellado RP (1999) Four genes encoding different type I signal peptidases are organized in a cluster in *Streptomyces lividans* TK21. *Microbiology* 145(Pt 9):2255–2263

Peng SB, Wang L, Moomaw J, Peery RB, Sun PM, Johnson RB, Lu J, Treadway P, Skatrud PL, Wang QM (2001) Biochemical characterization of signal peptidase I from gram-positive *Streptococcus pneumoniae*. *J Bacteriol* 183:621–627

Perlman D, Halvorson HO (1983) A putative signal peptidase recognition site and sequence in eukaryotic and prokaryotic signal peptides. *J Mol Biol* 167:391–409

Perry CR, Ashby MJ, Elsmere SA (1995) Penems as research tools to investigate the activity of *E. coli* leader peptidase. *Biochem Soc Trans* 23:548S

Petersen TN, Brunak S, von Heijne G, Nielsen H (2011) SignalP 4.0: discriminating signal peptides from transmembrane regions. *Nat Methods* 8:785–786

Pohlschroder M, Pfeiffer F, Schulze S, Halim MFA (2018) Archaeal cell surface biogenesis. *FEMS Microbiol Rev* 42:694–717

Pragai Z, Tjalsma H, Bolhuis A, van Dijl JM, Venema G, Bron S (1997) The signal peptidase II (Isp) gene of *Bacillus subtilis*. *Microbiology* 143(Pt 4):1327–1333

Rahman MS, Simser JA, Macaluso KR, Azad AF (2003) Molecular and functional analysis of the lepB gene, encoding a type I signal peptidase from *Rickettsia rickettsii* and *Rickettsia typhi*. *J Bacteriol* 185:4578–4584

Rahman MS, Ceraul SM, Dreher-Lesnick SM, Beier MS, Azad AF (2007) The lspA gene, encoding the type II signal peptidase of *Rickettsia typhi*: transcriptional and functional analysis. *J Bacteriol* 189:336–341

Rahman O, Cummings SP, Harrington DJ, Sutcliffe IC (2008) Methods for the bioinformatic identification of bacterial lipoproteins encoded in the genomes of Gram-positive bacteria. *World J Microbiol Biotechnol* 24:2377

Randall LL (1983) Translocation of domains of nascent periplasmic proteins across the cytoplasmic membrane is independent of elongation. *Cell* 33:231–240

Rawlings ND, Barrett AJ (2013) Chapter 1—introduction: aspartic and glutamic peptidases and their clans. In: *Handbook of proteolytic enzymes*. Academic Press, pp 3–19

Raynaud C, Charbit A (2005) Regulation of expression of type I signal peptidases in *Listeria monocytogenes*. *Microbiology* 151:3769–3776

Regue M, Remenick J, Tokunaga M, Mackie GA, Wu HC (1984) Mapping of the lipoprotein signal peptidase gene (lsp). *J Bacteriol* 158:632–635

Rizo J, Blanco FJ, Kobe B, Bruch MD, Giersch LM (1993) Conformational behavior of *Escherichia coli* OmpA signal peptides in membrane mimetic environments. *Biochemistry* 32:4881–4894

Roberts TC, Smith PA, Cirz RT, Romesberg FE (2007) Structural and initial biological analysis of synthetic arylomycin A2. *J Am Chem Soc* 129:15830–15838

Roberts TC, Schallenger MA, Liu J, Smith PA, Romesberg FE (2011a) Initial efforts toward the optimization of arylomycins for antibiotic activity. *J Med Chem* 54:4954–4963

Roberts TC, Smith PA, Romesberg FE (2011b) Synthesis and biological characterization of arylomycin B antibiotics. *J Nat Prod* 74:956–961

Sabatini DD, Blobel G, Nonomura Y, Adelman MR (1971) Ribosome-membrane interaction: structural aspects and functional implications. *Adv Cytopharmacol* 1:119–129

San Millan JL, Boyd D, Dalbey R, Wickner W, Beckwith J (1989) Use of phoA fusions to study the topology of the *Escherichia coli* inner membrane protein leader peptidase. *J Bacteriol* 171:5536–5541

Sankaram MB, Marsh D, Giersch LM, Thompson TE (1994) Reorganization of lipid domain structure in membranes by a transmembrane peptide: an ESR spin label study on the effect of the *Escherichia coli* outer membrane protein a signal peptide on the fluid lipid domain connectivity in

binary mixtures of dimyristoyl phosphatidylcholine and distearoyl phosphatidylcholine. *Biophys J* 66:1959–1968

Sankaran K, Gan K, Rash B, Qi HY, Wu HC, Rick PD (1997) Roles of histidine-103 and tyrosine-235 in the function of the prolipoprotein diacylglycerol transferase of *Escherichia coli*. *J Bacteriol* 179:2944–2948

Sarabia F, Chammaa S, Garcia-Ruiz C (2011) Solid phase synthesis of globomycin and SF-1902 A5. *J Org Chem* 76:2132–2144

Savojardo C, Martelli PL, Fariselli P, Casadio R (2018) DeepSig: deep learning improves signal peptide detection in proteins. *Bioinformatics* 34:1690–1696

Schimana J, Gebhardt K, Holtzel A, Schmid DG, Sussmuth R, Muller J, Pukall R, Fiedler HP (2002) Arylomycins A and B, new biaryl-bridged lipopeptide antibiotics produced by *Streptomyces* sp. Tu 6075. I. Taxonomy, fermentation, isolation and biological activities. *J Antibiot (Tokyo)* 55:565–570

Selas Castineiras T, Williams SG, Hitchcock A, Cole JA, Smith DC, Overton TW (2018) Development of a generic beta-lactamase screening system for improved signal peptides for periplasmic targeting of recombinant proteins in *Escherichia coli*. *Sci Rep* 8:6986

Seydel A, Gounon P, Pugsley AP (1999) Testing the ‘+ 2 rule’ for lipoprotein sorting in the *Escherichia coli* cell envelope with a new genetic selection. *Mol Microbiol* 34:810–821

Siegel SD, Wu C, Ton-That H (2016) A type I signal peptidase is required for pilus assembly in the Gram-positive, biofilm-forming bacterium *Actinomyces oris*. *J Bacteriol* 198:2064–2073

Smith PA, Romesberg FE (2012) Mechanism of action of the arylomycin antibiotics and effects of signal peptidase I inhibition. *Antimicrob Agents Chemother* 56:5054–5060

Smith AM, Yan H, Groves N, Dalla Pozza T, Walker MJ (2000) Co-expression of the *Bordetella* pertussis leader peptidase I results in enhanced processing and expression of the pertussis toxin S1 subunit in *Escherichia coli*. *FEMS Microbiol Lett* 191:177–182

Smith PA, Roberts TC, Romesberg FE (2010) Broad-spectrum antibiotic activity of the arylomycin natural products is masked by natural target mutations. *Chem Biol* 17:1223–1231

Smith PA, Powers ME, Roberts TC, Romesberg FE (2011) In vitro activities of arylomycin natural-product antibiotics against *Staphylococcus epidermidis* and other coagulase-negative staphylococci. *Antimicrob Agents Chemother* 55:1130–1134

Smith PA, Koehler MFT, Girgis HS, Yan D, Chen Y, Chen Y, Crawford JJ, Durk MR, Higuchi RI, Kang J et al (2018) Optimized arylomycins are a new class of Gram-negative antibiotics. *Nature* 561:189–194

Sung M, Dalbey RE (1992) Identification of potential active-site residues in the *Escherichia coli* leader peptidase. *J Biol Chem* 267:13154–13159

Szalaj N, Lu L, Benediktsdottir A, Zamaratski E, Cao S, Olanders G, Hedgecock C, Karlen A, Erdelyi M, Hughes D et al (2018) Boronic ester-linked macrocyclic lipopeptides as serine protease inhibitors targeting *Escherichia coli* type I signal peptidase. *Eur J Med Chem* 157:1346–1360

Talarico TL, Dev IK, Bassford PJ Jr, Ray PH (1991) Inter-molecular degradation of signal peptidase I in vitro. *Biochem Biophys Res Commun* 181:650–656

Terada M, Kuroda T, Matsuyama SI, Tokuda H (2001) Lipoprotein sorting signals evaluated as the LolA-dependent release of lipoproteins from the cytoplasmic membrane of *Escherichia coli*. *J Biol Chem* 276:47690–47694

Ting YT, Harris PW, Batot G, Brimble MA, Baker EN, Young PG (2016) Peptide binding to a bacterial signal peptidase visualized by peptide tethering and carrier-driven crystallization. *IUCrJ* 3:10–19

Tjalsma H, Noback MA, Bron S, Venema G, Yamane K, van Dijl JM (1997) *Bacillus subtilis* contains four closely related type I signal peptidases with overlapping substrate specificities. Constitutive and temporally controlled expression of different sip genes. *J Biol Chem* 272:25983–25992

Tjalsma H, Bolhuis A, van Roosmalen ML, Wiegert T, Schumann W, Broekhuizen CP, Quax WJ, Venema G, Bron S, van Dijl JM (1998) Functional analysis of the secretory precursor processing machinery of *Bacillus subtilis*: identification of a eubacterial homolog of archaeal and eukaryotic signal peptidases. *Genes Dev* 12:2318–2331

Tjalsma H, Kontinen VP, Pragai Z, Wu H, Meima R, Venema G, Bron S, Sarvas M, van Dijl JM (1999a) The role of lipoprotein processing by signal peptidase II in the Gram-positive eubacterium *bacillus subtilis*. Signal peptidase II is required for the efficient secretion of alpha-amylase, a non-lipoprotein. *J Biol Chem* 274:1698–1707

Tjalsma H, van den Dolder J, Meijer WJ, Venema G, Bron S, van Dijl JM (1999b) The plasmid-encoded signal peptidase SipP can functionally replace the major signal peptidases SipS and SipT of *Bacillus subtilis*. *J Bacteriol* 181:2448–2454

Tjalsma H, Zanen G, Venema G, Bron S, van Dijl JM (1999c) The potential active site of the lipoprotein-specific (type II) signal peptidase of *Bacillus subtilis*. *J Biol Chem* 274:28191–28197

Tjalsma H, Stover AG, Driks A, Venema G, Bron S, van Dijl JM (2000) Conserved serine and histidine residues are critical for activity of the ER-type signal peptidase SipW of *Bacillus subtilis*. *J Biol Chem* 275:25102–25108

Tokuda H, Matsuyama S (2004) Sorting of lipoproteins to the outer membrane in *E. coli*. *Biochim Biophys Acta* 1693:5–13

Tokunaga M, Loranger JM, Wolfe PB, Wu HC (1982) Prolipoprotein signal peptidase in *Escherichia coli* is distinct from the M13 procoat protein signal peptidase. *J Biol Chem* 257:9922–9925

Tokunaga M, Loranger JM, Wu HC (1984) A distinct signal peptidase for prolipoprotein in *Escherichia coli*. *J Cell Biochem* 24:113–120

Tschantz WR, Sung M, Delgado-Partin VM, Dalbey RE (1993) A serine and a lysine residue implicated in the catalytic mechanism of the *Escherichia coli* leader peptidase. *J Biol Chem* 268:27349–27354

Tschantz WR, Paetzel M, Cao G, Suciu D, Inouye M, Dalbey RE (1995) Characterization of a soluble, catalytically active form of *Escherichia coli* leader peptidase: requirement of detergent or phospholipid for optimal activity. *Biochemistry* 34:3935–3941

Tsirigotaki A, De Geyter J, Sostaric N, Economou A, Karamanou S (2017) Protein export through the bacterial Sec pathway. *Nat Rev Microbiol* 15:21–36

Tullman-Ercek D, DeLisla MP, Kawarasaki Y, Iranpour P, Ribnicky B, Palmer T, Georgiou G (2007) Export pathway selectivity of *Escherichia coli* twin arginine translocation signal peptides. *J Biol Chem* 282:8309–8316

Tyndall JD, Nall T, Fairlie DP (2005) Proteases universally recognize beta strands in their active sites. *Chem Rev* 105:973–999

Ujiie A, Nakano H, Iwasaki Y (2016) Extracellular production of *Pseudozyma* (*Candida*) antarctica lipase B with genuine primary sequence in recombinant *Escherichia coli*. *J Biosci Bioeng* 121:303–309

UniProt C (2013) Update on activities at the Universal Protein Resource (UniProt) in 2013. *Nucleic Acids Res* 41:D43–D47

van Dijl JM, van den Bergh R, Reversma T, Smith H, Bron S, Venema G (1990) Molecular cloning of the *Salmonella typhimurium* lep gene in *Escherichia coli*. *Mol Gen Genet* 223:233–240

van Dijl JM, de Jong A, Vehmaanpera J, Venema G, Bron S (1992) Signal peptidase I of *Bacillus subtilis*: patterns of conserved amino acids in prokaryotic and eukaryotic type I signal peptidases. *EMBO J* 11:2819–2828

van Dijl JM, de Jong A, Venema G, Bron S (1995) Identification of the potential active site of the signal peptidase SipS of *Bacillus subtilis*. Structural and functional similarities with LexA-like proteases. *J Biol Chem* 270:3611–3618

van Klompenburg W, Whitley P, Diemel R, von Heijne G, de Kruijff B (1995) A quantitative assay to determine the amount of signal peptidase I in *E. coli* and the orientation of membrane vesicles. *Mol Membr Biol* 12:349–353

van Klompenburg W, Ridder AN, van Raalte AL, Killian AJ, von Heijne G, de Kruijff B (1997) In vitro membrane integration of leader peptidase depends on the Sec machinery and anionic phospholipids and can occur post-translationally. *FEBS Lett* 413:109–114

van Klompenburg W, Paetzel M, de Jong JM, Dalbey RE, Demel RA, von Heijne G, de Kruijff B (1998) Phosphatidylethanolamine mediates insertion of the catalytic domain of leader peptidase in membranes. *FEBS Lett* 431:75–79

van Roosmalen ML, Jongbloed JD, de Jonf A, van Eerden J, Venema G, Bron S, van Dijl JM (2001) Detergent-independent in vitro activity of a truncated *Bacillus* signal peptidase. *Microbiology* 147:909–917

Vogeley L, El Arnaout T, Bailey J, Stansfeld PJ, Boland C, Caffrey M (2016) Structural basis of lipoprotein signal peptidase II action and inhibition by the antibiotic globomycin. *Science* 351:876–880

von Heijne G (1983) Patterns of amino acids near signal-sequence cleavage sites. *Eur J Biochem* 133:17–21

von Heijne G (1985) Signal sequences. The limits of variation. *J Mol Biol* 184:99–105

Voorhees RM, Hegde RS (2016) Toward a structural understanding of co-translational protein translocation. *Curr Opin Cell Biol* 41:91–99

Waite RD, Rose RS, Rangarajan M, Aduse-Opoku J, Hashim A, Curtis MA (2012) *Pseudomonas aeruginosa* possesses two putative type I signal peptidases, LepB and PA1303, each with distinct roles in physiology and virulence. *J Bacteriol* 194:4521–4536

Wang Z, Jones JD, Rizo J, Giersch LM (1993) Membrane-bound conformation of a signal peptide: a transferred nuclear Overhauser effect analysis. *Biochemistry* 32:13991–13999

Wang S, Wang D, Li J, Huang T, Cai YD (2018) Identification and analysis of the cleavage site in a signal peptide using SMOTE, dagging, and feature selection methods. *Mol Omics* 14:64–73

Watts C, Silver P, Wickner W (1981) Membrane assembly from purified components. II. Assembly of M13 procoat into liposomes reconstituted with purified leader peptidase. *Cell* 25:347–353

Whitley P, Nilsson L, von Heijne G (1993) Three-dimensional model for the membrane domain of *Escherichia coli* leader peptidase based on disulfide mapping. *Biochemistry* 32:8534–8539

Wieseler B, Schiltz E, Muller M (1992) Identification and solubilization of a signal peptidase from the phototrophic bacterium *Rhodobacter capsulatus*. *FEBS Lett* 298:273–276

Witke C, Gotz F (1995) Cloning and nucleotide sequence of the signal peptidase II (lsp)-gene from *Staphylococcus carnosus*. *FEMS Microbiol Lett* 126:233–239

Wlodawer A, Gustchina A, James MNG (2013) Chapter 2—catalytic pathways of aspartic peptidases. In: *Handbook of proteolytic enzymes*. Academic Press, pp 19–26

Wolfe PB, Wickner W, Goodman JM (1983) Sequence of the leader peptidase gene of *Escherichia coli* and the orientation of leader peptidase in the bacterial envelope. *J Biol Chem* 258:12073–12080

Xiao Y, Gerth K, Muller R, Wall D (2012) *Myxobacterium*-produced antibiotic TA (myxovirescin) inhibits type II signal peptidase. *Antimicrob Agents Chemother* 56:2014–2021

Yamagata H (1983) Temperature-sensitive prolipoprotein signal peptidase in an *Escherichia coli* mutant: use of the mutant for an efficient and convenient assay system. *J Biochem* 93:1509–1515

Yeh CH, Walsh SI, Craney A, Tabor MG, Voica AF, Adhikary R, Morris SE, Romesberg FE (2018) Optimization of a beta-lactam scaffold for antibacterial activity via the inhibition of bacterial type I signal peptidase. *ACS Med Chem Lett* 9:376–380

Zhang YB, Greenberg B, Lacks SA (1997) Analysis of a *Streptococcus pneumoniae* gene encoding signal peptidase I and overproduction of the enzyme. *Gene* 194:249–255

Zhang W, Lu J, Zhang S, Liu L, Pang X, Lv J (2018) Development an effective system to expression recombinant protein in *E. coli* via comparison and optimization of signal peptides: expression of *Pseudomonas fluorescens* BJ-10 thermostable lipase as case study. *Microb Cell Fact* 17:50

Zhbanko M, Zinchenko V, Guttensohn M, Schierhorn A, Klosgen RB (2005) Inactivation of a predicted leader peptidase prevents photoautotrophic growth of *Synechocystis* sp. strain PCC 6803. *J Bacteriol* 187:3071–3078

Zheng F, Angleton EL, Lu J, Peng SB (2002) In vitro and in vivo self-cleavage of *Streptococcus pneumoniae* signal peptidase I. *Eur J Biochem* 269:3969–3977

Zuckert WR (2014) Secretion of bacterial lipoproteins: through the cytoplasmic membrane, the periplasm and beyond. *Biochim Biophys Acta* 1843:1509–1516

Zwizinski C, Wickner W (1980) Purification and characterization of leader (signal) peptidase from *Escherichia coli*. *J Biol Chem* 255:7973–7977

Zwizinski C, Date T, Wickner W (1981) Leader peptidase is found in both the inner and outer membranes of *Escherichia coli*. *J Biol Chem* 256:3593–3597